| The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. | |
| | |
MedLine Citation:
|
PMID: 15980058 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In this study, we investigated antiparkinsonian activity of the novel, highly selective dopamine D(2) receptor agonist sumanirole compared with two clinically effective dopaminergic therapies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Squirrel monkeys were rendered parkinsonian by chronic administration of MPTP and subsequently dosed with vehicle, L-DOPA plus carbidopa (L-DOPA), ropinirole, or sumanirole over a duration of 8 weeks. Antiparkinsonian effects measured with a parkinsonian primate rating scale (PPRS) showed that sumanirole elicited improved functional outcome compared with vehicle. The dopamine D2/D3 agonist ropinirole improved behavioral outcome similar to sumanirole, whereas L-DOPA treatment yielded the most significant symptomatic improvement. The relative rank of therapies that elicited normalization of PPRS was L-DOPA > sumanirole; ropinirole did not normalize PPRS in any of the treated monkeys. Dyskinesias were present with L-DOPA treatment but were not observed in sumanirole-, ropinirole-, or placebo-treated primates. Pathologically, all MPTP-treated animals displayed neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta and reactive astrocytosis. Neurons immunoreactive with antibodies to the nuclear transcription factor DeltaFosB were most significantly increased in the striatum of L-DOPA-treated monkeys. These results suggest that sumanirole can exert antiparkinsonian effects similar to L-DOPA without the behavioral and morphological consequences of the latter. |
| | |
Authors:
|
Diane T Stephenson; Martin D Meglasson; Mark A Connell; Mary A Childs; Eva Hajos-Korcsok; Marina E Emborg |
Related Documents
:
|
23299048 - Exercise for anxiety disorders: systematic review. 15991218 - Does "excessive" or "compulsive" best describe exercise as a symptom of bulimia nervosa? 21962488 - 'so few fat ones grow old': diet, health, and virtue in the golden age of rising life e... 16879808 - Telencephalic ablation results in decreased startle response in goldfish. 3121578 - Chemoreflex modulation of ventilatory dynamics during exercise in humans. 20842088 - Effects of music during exercise in different training status. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2005-06-24 |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 314 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2005-08-22 Completed Date: 2005-10-21 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1257-66 Citation Subset: IM |
Affiliation:
|
Pfizer Global Research and Development, Groton, CT 06340, USA. diane.t.stephenson@pfizer.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Basal Ganglia / pathology Benzimidazoles / pharmacokinetics, therapeutic use* Biogenic Monoamines / cerebrospinal fluid Dopamine Agonists / therapeutic use* Levodopa / therapeutic use MPTP Poisoning / drug therapy*, pathology, psychology Male Motor Activity / drug effects Receptors, Dopamine D2 / agonists* Saimiri Substantia Nigra / pathology |
| Grant Support | |
ID/Acronym/Agency:
|
P51RR000167/RR/NCRR NIH HHS; R01-NS40578/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Benzimidazoles; 0/Biogenic Monoamines; 0/Dopamine Agonists; 0/Levodopa; 0/Receptors, Dopamine D2; 0/U 95666E |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimenta...
Next Document: Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes.